Back to Search

MATTHEW VOLM, MD

MD

Hematology & Oncology Physician

NPI: 1508867185Individual

Specialties, Licenses & Credentials

Hematology & Oncology PhysicianPrimary

Internal Medicine — Hematology & Oncology

Code: 207RH0003X

188392(NY)

Research & Publications (20)

Male breast cancer.
PMID 12594942·Curr Treat Options Oncol·2003
6-review
Prognostic relevance of angiogenic, proliferative, and apoptotic factors in lung carcinomas. A case review.
PMID 12415702·Methods Mol Med·2003
6-review
Cellular predictive factors of drug resistance in non-small cell lung carcinomas.
PMID 12407734·Methods Mol Med·2003
8-other
Protein expression profile of primary human squamous cell lung carcinomas indicative of the incidence of metastases.
PMID 12198766·Clin Exp Metastasis·2002
8-other
Protein expression profiles indicative for drug resistance of non-small cell lung cancer.
PMID 12177790·Br J Cancer·2002
8-other
Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients.
PMID 12060626·Clin Cancer Res·2002
8-other
Association of telomerase expression with successful heterotransplantation of lung cancer.
PMID 10601545·Int J Oncol·2000
4-observational
CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.
PMID 19676044·Int J Cancer·2010
7-preclinical
Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure.
PMID 18677966·Arzneimittelforschung·2008
6-review
Prediction of broad spectrum resistance of tumors towards anticancer drugs.
PMID 18413831·Clin Cancer Res·2008
8-other
Resistance in malignant tumors: can resistance assays optimize cytostatic chemotherapy?
PMID 18176090·Pharmacology·2008
6-review
Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
PMID 17919349·Clin Breast Cancer·2007
3-trial
Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression.
PMID 16249352·Oncologist·2005
8-other
Pharmacogenetics for individualized cancer chemotherapy.
PMID 15890408·Pharmacol Ther·2005
6-review
Molecular modes of action of artesunate in tumor cell lines.
PMID 12869643·Mol Pharmacol·2003
4-observational
Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies.
PMID 12679737·Anticancer Drugs·2003
3-trial
Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial.
PMID 12610186·J Clin Oncol·2003
3-trial
Characteristics of long-term survivors of untreated lung cancer.
PMID 12009238·Lung Cancer·2002
8-other
Expression profile of proteins involved in the xenotransplantability of non-small cell lung cancers into athymic nude mice.
PMID 11788907·Int J Oncol·2002
7-preclinical
Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction.
PMID 11705851·Clin Cancer Res·2001
8-other

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
160 E 34TH ST, 4TH FL.
NEW YORK, NY 10016

Location

Practice Location

160 E 34TH ST, NEW YORK, NY
(212) 731-5433

Quick Facts

NPI
1508867185
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
1
Locations
1
Publications
20

Are you this provider?

Claim Your Profile